A pooled analysis of two large clinical trials suggests that tirzepatide can substantially improve blood-sugar control in people with type 2 diabetes whose glucose levels remain too high despite treatment with basal insulin. The study, published on 10 April 2026 in Diabetes Therapy, examined whether the drug’s effects were consistent across patients of different ages, diabetes durations, starting HbA1c levels and basal-insulin doses. Researchers combined data from 1,072 participants in the SURPASS-5 and SURPASS-6 trials, focusing on tirzepatide as an add-on therapy rather than as a replacement for insulin. The findings are important because many people with type 2 diabetes eventually require insulin but still struggle to reach recommended glucose targets, often while facing treatment-related weight gain and concerns about hypoglycemia.
Tirzepatide is a once-weekly injectable medicine that activates two hormone receptors: those for glucose-dependent insulinotropic polypeptide, or GIP, and glucagon-like peptide-1, or GLP-1. These hormones are released by the intestine after eating and help coordinate the body’s response to food. Tirzepatide enhances insulin secretion when blood glucose is elevated, suppresses the release of glucagon, slows the movement of food through the stomach and reduces appetite. Because its effects on insulin secretion are largely glucose dependent, the drug is designed to lower glucose without continuously forcing the pancreas to release insulin when blood sugar is already low. That mechanism makes it an attractive partner for basal insulin, which provides a steady background supply of insulin but does not always control the sharp glucose rises that follow meals.
Basal insulin is commonly prescribed when tablets and other non-insulin treatments are no longer sufficient. It is usually adjusted upward until fasting glucose reaches a target range, yet this strategy can leave post-meal glucose excursions inadequately controlled. Increasing insulin doses can also cause weight gain and raise the risk of hypoglycemia, particularly when the treatment is intensified without addressing appetite, gastric emptying and glucagon activity. The SURPASS studies tested whether adding tirzepatide could address several of these problems at once. In SURPASS-5, participants receiving basal insulin were assigned to tirzepatide or placebo. In SURPASS-6, tirzepatide was compared with insulin lispro, a rapid-acting mealtime insulin. In both studies, the insulin treatments were titrated toward predefined glucose targets, allowing investigators to compare tirzepatide with active insulin intensification rather than with an unchanged background regimen.
The new report was an exploratory post hoc subgroup analysis, meaning that the researchers examined previously collected trial data after the original studies had been completed. The participants were divided according to baseline HbA1c, age, duration of type 2 diabetes and basal-insulin dosage. HbA1c is a blood marker that reflects average glucose exposure over roughly two to three months; a value above 8.5 percent indicates particularly poor glycemic control in the context of these trials. The analysis therefore asked a practical clinical question: does tirzepatide work mainly in a narrow group of relatively young people with recently diagnosed diabetes, or can it also help patients with long-standing disease, higher starting HbA1c and substantial insulin requirements? The investigators evaluated changes in HbA1c, body weight and hypoglycemia safety across the subgroups.
Across the pooled population, tirzepatide produced marked improvements in glycemic control when added to basal insulin. The reductions in HbA1c were generally consistent across the prespecified categories, including people who began treatment with HbA1c at or below 8.5 percent and those whose levels were higher. This consistency matters because severe insulin resistance and longer disease duration can reduce the body’s remaining capacity to produce insulin. Tirzepatide does not simply provide another source of insulin; it amplifies nutrient-dependent hormone signalling, improves insulin sensitivity indirectly through weight loss and suppresses excessive glucagon. The trial results indicate that these effects remained clinically meaningful even when the underlying diabetes was more advanced or when participants were already receiving higher basal-insulin doses.
The analysis also reinforced the drug’s effects on body weight, an outcome that distinguishes tirzepatide from simply adding more insulin. In the original SURPASS programs, tirzepatide was associated with weight loss, whereas insulin-based intensification generally led to weight gain or little change. That difference is biologically significant. Excess adipose tissue, particularly visceral fat, contributes to insulin resistance through inflammatory signalling and altered lipid metabolism. Weight reduction can lower the amount of insulin required to control glucose and may improve the efficiency of insulin action in muscle and liver. Tirzepatide’s appetite-suppressing and gastric-emptying effects reduce energy intake, while its metabolic actions improve the handling of glucose after meals. The pooled findings suggest that the weight benefit was not restricted to a particular age group or starting insulin dose, although individual responses varied.
Hypoglycemia was another central focus of the study. Any treatment added to insulin must be judged not only by how far it lowers HbA1c but also by whether it drives glucose dangerously low. Tirzepatide’s glucose-dependent mechanism theoretically limits insulin release when glucose concentrations fall, but basal insulin remains capable of causing hypoglycemia. In SURPASS-5 and SURPASS-6, insulin doses were actively adjusted according to protocol, and the pooled analysis assessed episodes of clinically important low blood sugar across the different participant subgroups. The overall safety pattern supported the use of tirzepatide alongside basal insulin without suggesting that the drug created a new, subgroup-specific hypoglycemia signal. Nonetheless, the findings do not eliminate the need for careful insulin titration, glucose monitoring and individualized dose reductions when glucose levels improve rapidly.
The comparison with SURPASS-6 is particularly relevant to everyday treatment decisions. When a patient using basal insulin remains above target, clinicians often add rapid-acting insulin before meals. That approach can be effective, but it requires multiple daily injections, frequent glucose checks and detailed adjustment of meal-time doses. It may also increase the risk of hypoglycemia and promote weight gain. In SURPASS-6, tirzepatide was tested against insulin lispro, providing a direct comparison between a weekly incretin-based therapy and conventional mealtime insulin intensification. The pooled report does not suggest that every patient should abandon prandial insulin, but it adds evidence that a dual GIP/GLP-1 receptor agonist can be a potent alternative for many people who need better control despite basal insulin.
The researchers caution that the analysis has limitations. Because it was conducted after the original trials and was not primarily designed to compare every subgroup, the findings should be interpreted as exploratory rather than as definitive proof that the drug performs identically in all patient categories. The two trials also differed in their comparators, treatment durations and study designs: placebo was used in SURPASS-5, while insulin lispro was used in SURPASS-6. Participants enrolled in randomized clinical trials may also receive more intensive follow-up than people treated in routine practice. In addition, the analysis examined selected baseline characteristics and cannot establish how tirzepatide would perform in every population, including people with severe kidney disease, advanced frailty or type 1 diabetes. Gastrointestinal adverse effects, such as nausea, diarrhea and vomiting, remain relevant considerations for treatment decisions.
Even with those caveats, the findings strengthen the case for tirzepatide as a flexible intensification option for people whose type 2 diabetes remains uncontrolled on basal insulin. The clinical appeal lies in the combination of effects: lower HbA1c, reduced body weight and no obvious loss of hypoglycemia safety across the examined subgroups. The results also highlight a broader shift in diabetes treatment, away from viewing glucose control as a problem solved only by adding more insulin. Modern therapies can target appetite, gut-hormone signalling, glucagon biology and insulin sensitivity simultaneously. For patients and clinicians, the practical question is no longer simply whether insulin should be increased, but which strategy can improve glucose control while minimizing the metabolic costs of treatment. The pooled SURPASS-5 and SURPASS-6 analysis suggests that, for a wide range of adults using basal insulin, tirzepatide may be one of the most powerful answers currently available.
